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Verification of the Newly Proposed T Category (Seventh
Edition of the Tumor, Node, and Metastasis Classification)
from a Clinicopathological Viewpoint in Non-small Cell
Lung Cancer—Special Reference to Tumor Size
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Introduction: This study first verified the T classification, which is
the major point of the revision regarding the seventh Tumor, Node,
and Metastasis classification, from a viewpoint of the clinicopatho-
logical findings at the primary tumor site in non-small cell lung
cancer.
Methods: The medical records of 1393 patients with non-small cell
lung cancer who underwent a complete resection at this hospital
from 1974 to 2003 were thoroughly reviewed for pathologic findings
and survival.
Results: According to greatest dimension of the primary tumors, the
5-year postoperative survival was 77.8% for T1a (2 cm), 63.3%
for T1b (3 cm), 46.4% for T2a (5 cm), 38.8% for T2b (7 cm),
and 21.4% for T3 (7 cm). The differences among those new T
categories were all statistically significant. The incidence of lym-
phatic permeation within the primary tumor was 17.2% for T1b and
29.8% for T2a (T1b versus T2a, p  0.05). The incidence of
vascular invasion within the primary tumor was 24.9% for T1b,
35.3% for T2a, and 54.2% for T2b (T1b versus T2a and T2a versus
T2b, p  0.05). On the other hand, the incidence of pleural invasion
of the primary tumor was 18.1% for T1a, 29.4% for T1b, 49.3% for
T2a, 47.3% for T2b, and 87.5% for T3 (T1a versus T1b, T1b versus
T2a, T2b versus T3, p  0.05). Significant differences were ob-
served among the newly revised T subsets in at least one incidence
of lymphatic, vascular, or pleural invasion.
Conclusion: The new T classification, which is based mainly on the
tumor size, is therefore considered to be appropriate for the patho-
logic findings of the primary tumor.
Key Words: Non-small cell lung cancer, TNM classification, Tu-
mor size, Intratumoral vessel invasion, Pleural invasion.
(J Thorac Oncol. 2010;5: 45–48)
Primary lung cancer is one of the most common malignan-cies in the world. It has been the leading cause of cancer
death in Japan since 1998 and is still increasing in both
prevalence and mortality. Despite recent progress in both
radiotherapy and chemotherapy, a surgical resection remains
the first choice of treatment for stages I to IIIA non-small cell
lung cancer (NSCLC). However, the surgical results for
patients with locally advanced stages (II or IIIA) are not
satisfactory, even if a complete resection can be performed,
and the 5-year survival rate is less than 50%.1,2 Various
effective modalities of the treatment are now warranted to
improve the prognosis.
The tumor, node, and metastasis (TNM) staging system
is useful for both the clinical assessment of tumor progression
and the determination of treatment modality in various kinds
of malignancy. In the forthcoming seventh edition of the
TNM classification, a revision with respect to lung cancer has
been proposed by the International Association for the Study
of Lung Cancer.3–6 The major revision is the T category,
which makes an especially strict division by detailed cut
points of tumor size such as 2, 3, 5, and 7 cm.4 The proposed
T revision has been determined and validated based on the
overall survival data from a large international database.
In addition to conventional TNM staging including
pleural invasion, pathologic evaluation of intratumoral vessel
invasion (both blood vessels and lymphatic vessels) has been
used as an indicator of tumor invasiveness in surgically
resected NSCLC.7 In fact, several studies have shown that the
intratumoral vessel invasion is a significant prognostic factor,
especially for pathologic stage I disease.8–13
This study first verified the T classification, which was
the major point of revision regarding the newly proposed
TNM classification, from a viewpoint of the clinicopatholog-
ical findings at the primary tumor site, including microscopic
vessel invasion and pleural invasion.
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PATIENTS AND METHODS
Patients
The medical records of 1393 patients with primary
NSCLC who underwent a complete resection in Kyushu
University Hospital from 1974 to 2003 were thoroughly
reviewed for pathologic diagnosis (histologic types and dis-
ease stage) and survival. This study was approved by the
Kyushu University Institutional Review Board for Clinical
Research.
The patients ranged in age from 23 to 87 years with a
mean of 64.4 and included 939 men and 454 women. The
histologic types were adenocarcinoma in 848 patients and
nonadenocarcinoma in 545 patients. The stage of all the
patients was pathologically defined according to the present
international staging system previously revised in 1997.1,14
Despite the performance of a systematic hilar-mediastinal
lymph node dissection, the resection was regarded as com-
plete if all the macroscopic tumors had been removed without
any microscopically residual tumors at the surgical margin.
The extent of the pulmonary resection was a pneumonectomy
in 135 patients (9.7%), a lobectomy in 1172 patients (84.1%),
a segmentectomy in 31 patients (2.2%), and a wedge resec-
tion in 55 patients (3.9%). Systematic hilar-mediastinal
lymph node dissection was performed in 1032 patients
(73.7%). Perioperative adjuvant treatment was not routinely
performed during the entire period. From February 1993 to
January 1995, 42 patients were enrolled into a clinical trial
for the postoperative adjuvant chemotherapy, and 22 patients
received combination chemotherapy of cisplatin plus oral
tegafur and uracil.
A survival analysis was performed using the data of all
the patients. A clinicopathological analysis was performed
using the data of 621 patients that underwent a resection from
1990 to 2003, in whom the histopathological assessment of
intratumoral vessel invasion was available in addition to that
of pleural invasion. Written informed consent for the com-
prehensive use of histopathologic analyses was obtained from
each patient.
Follow-Up of Postoperative Patients
A routine check-up with a physical examination, blood
cell counts, serum chemistry, serum tumor markers including
carcinoembryonic antigen and cytokeratin fragment 19, and
chest x-rays were performed on an outpatient basis four times
a year for the first 3 years, and thereafter twice annually.
Since 1983, computed tomography and bone scans were
performed twice a year for the first 3 years, and thereafter at
least annually. Systemic chemotherapy and/or radiation were
administered when a relapse was diagnosed, if it was feasible.
Histopathologic Evaluation
Formalin-fixed and paraffin-embedded surgical speci-
mens were routinely used for the histopathological diagnosis
at the department of pathology in Kyushu University Hospi-
tal. In addition to hematoxylin-eosin staining, Elastica van Gie-
son staining was applied for the evaluation of visceral pleural
invasion and intratumoral vessel invasion. Pleural invasion was
defined to extend beyond the elastic pleural layer. Both
vascular invasion and lymphatic permeation indicated tumor
cells identifiable in the vessel lumen in the maximal cut-
surface specimen of the primary tumor. The identification of
blood vessels was dependent on the presence of either elastic
tissue around the vessels or erythrocytes in the lumen.
Statistics
For the analyses of the overall survival, each patient’s
time period began on the date of surgery and ended on the
date of death or the last date of follow-up. The univariate
survival analyses were estimated by the Kaplan-Meier test,
and the differences among the groups were analyzed by the
log-rank test. Comparisons of the clinicopathological vari-
ables among the T categories depending on tumor sizes were
performed using Fisher’s exact test. A two-sided p  0.05
was considered to be statistically significant.
RESULTS
According to greatest dimension of the primary tumors
with any pathologic node (pN) status, the 5-year postopera-
tive survival was 77.8% for T1a (2 cm; n 298), 63.3% for
T1b (2–3 cm; n 344), 46.4% for T2a (3–5 cm; n
485), 38.8% for T2b (5–7 cm; n  180), and 21.4% for
T3 (7 cm; n  86). The differences among those new T
categories were all statistically significant (Figure 1). Except
for 168 cases with a pN1 status and 314 cases with a pN2
status, the 5-year postoperative survival in the 911 cases of
only pN0 status was 83.9% for T1a (n 246), 74.6% for T1b
(n 237), 59.5% for T2a (n 283), 53.5% for T2b (n 95),
and 30.8% for T3 (n 50). Except for the difference between
T2a and T2b, the differences among the T categories were
also statistically significant (Figure 2).
Table 1 shows the correlation between the new T
categories (greatest dimension of primary tumor) and the
incidence of intratumoral vessel invasion or pleural invasion
regarding the 621 patients from 1990 to 2003. The incidence
of lymphatic permeation within the primary tumor was 12.5%
for T1a, 17.2% for T1b, 29.8% for T2a, 35.4% for T2b, and
FIGURE 1. T1a (n  298) versus T1b (n  344), p  0.001;
T1b versus T2a (n  485), p  0.001; T2a versus T2b (n 
180), p  0.012; and T2b versus T3 (n  86), p  0.002.
Yano et al. Journal of Thoracic Oncology • Volume 5, Number 1, January 2010
Copyright © 2009 by the International Association for the Study of Lung Cancer46
32.3% for T3 (T1b versus T2a, p  0.01). The incidence of
vascular invasion within the primary tumor was 17.8% for
T1a, 24.9% for T1b, 35.3% for T2a, 54.2% for T2b, and
64.5% for T3 (T1b versus T2a and T2a versus T2b, p 
0.05). On the other hand, the incidence of pleural invasion of
the primary tumor was 18.1% for T1a, 29.4% for T1b, 49.3%
for T2a, 47.3% for T2b, and 87.5% for T3 (T1a versus T1b,
p  0.05; T1b versus T2a and T2b versus T3, p  0.001).
Significant differences were observed among the newly re-
vised T subsets in at least one incidence of lymphatic per-
meation, vascular invasion, or pleural invasion.
Regarding the 432 cases limited to pN0 status (Table
2), significant differences were also observed among the T
subsets in at least one incidence of lymphatic permeation
(T1a versus T1b, p  0.05), vascular invasion (T2a versus
T2b, p  0.05), or pleural invasion (T1b versus T2a, p 
0.001; T2b versus T3, p  0.05).
DISCUSSION
This study examined the relationship between the cut-
off points of the tumor size for the new T category and the
pathologic tumor invasiveness including intratumoral vessel
invasion and pleural invasion of surgically resected NSCLC.
Among the five tumor-size categories, significant differences
were recognized at least in one incidence of lymphatic per-
meation, vascular invasion, or pleural invasion, when both
cases with any pN status and only those with pN0 status were
analyzed. Therefore, the newly revised T classification,
which is based mainly on the tumor dimension, is considered
both effective and appropriate for the clinicopathological
findings of the primary tumor.
The forthcoming revision of the TNM classification has
been determined and validated based on the overall survival
data from a large international database.3 However, the over-
all survival is affected by the differences of both the popu-
lation (ethnicity, gender, age, histologic types, etc.) and
treatment modality among the countries. For example, in
Asian countries, NSCLC in never smokers has been increas-
ing, which is characterized by female gender, adenocarci-
noma histology, and better prognosis in comparison with that
in both current and former smokers.15–19 Furthermore, those
patients with adenocarcinoma increasing in Asian countries
are likely to be sensitive to epithelial growth factor receptor-
tyrosine kinase inhibitors such as gefitinib and show a sur-
vival benefit from such treatment.20–22 On the other hand, the
survival differences between the platinum doublet regimens,
i.e., cisplatin plus gemcitabine and cisplatin plus pemetrexed
according to histology have been recently reported.23 There-
fore, in addition to survival validation, the TNM classification
should be also validated from the aspect of pathologic tumor
invasiveness, using surgical specimens.
Microscopic characterizations of tumor invasiveness or
malignant potential at the primary tumor site include intratu-
moral lymphatic and vascular vessel invasion and pleural
invasion. Of those, pleural invasion (p2 or more) has been
conventionally used in the determination of TNM classifica-
tion.1,14 Between the tumors of 3 cm or smaller (conventional
T1) and those of larger than 3 cm (conventional T2), the
incidences of all the aforementioned microscopic indicators
of tumor invasiveness were significantly different in the
analysis of the cases with any pN status (Table 1). Therefore,
the conventionally used cutoff point of 3 cm between T1 and
T2 was confirmed to be very effective and appropriate for the
FIGURE 2. T1a (n  246) versus T1b (n  237), p  0.004;
T1b versus T2a (n  283), p  0.001; T2a versus T2b (n 
95), p  0.181; and T2b versus T3 (n  50), p  0.016.
TABLE 1. Incidence of Invasive Growth within the Primary















2 cm (T1a) 168 12.5 17.8 18.1a
2 cm  3 cm (T1b) 169 17.2b 24.9a 29.4a,c
3 cm  5 cm (T2a) 205 29.8b 35.3a 49.3c
5 cm  7 cm (T2b) 48 35.4 54.2a 47.3c
7 cm (T3) 31 32.2 64.5 87.5c
a p  0.05.
b p  0.01.
c p  0.001.
TABLE 2. Incidence of Invasive Growth within the Primary
















2 cm (T1a) 132 4.5a 12.0 16.7
2 cm  3 cm (T1b) 125 12.0a 14.4 20.6b
3 cm  5 cm (T2a) 126 16.7 24.2a 44.8b
5 cm  7 cm (T2b) 29 24.1 44.8a 48.6a
7 cm (T3) 20 20.0 55.0 84.2a
a p  0.05.
b p  0.001.
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whole TNM system. In the analysis limited to pN0 cases, a
significant difference in the incidence of lymphatic perme-
ation between the new T1a and T1b was interestingly found
to coincide with that in postoperative survival. Thus, it is
suggested that the therapeutic strategy of T1a disease and T1b
disease, especially the application of postoperative adjuvant
chemotherapy, might thus be different, even though both
diseases are still classified as the same stage IA disease.
On the other hand, a significant difference was seen in
the vascular invasion between the tumors measuring 5 cm or
smaller (new T2a) and those of larger than 5 cm (new T2b) in
the analysis of both any type of pN cases and that limited to
pN0 cases. Although the difference in the overall survival
between those two tumors with a pN0 status was not statis-
tically significant, probably due to being statistically under-
powered, the newly proposed division of T2 disease is nev-
ertheless considered to be appropriate.
In conclusion, the newly revised T classification, which
is mainly based on the dimensions of the tumor, is considered
to be both effective and appropriate for determining the
pathologic invasiveness of the primary tumor.
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